A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
NCT ID: NCT00000859
Last Updated: 2021-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1300 participants
INTERVENTIONAL
2001-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\[AS PER AMENDMENT 10/02/97: To compare by intention-to-treat analysis for disease progression, including death, the following two regimens: NFV plus background combination antiretroviral (AR) therapy followed by indinavir (IDV) or RTV in the event of significant intolerance; and RTV plus AR therapy followed by IDV, then NFV, in the event of significant intolerance.\] \[AS PER AMENDMENT 3/11/98: SUBSTUDY CPCRA 045: To determine the relative rates of emergence of HIV-1 resistance and to compare changes in plasma HIV RNA levels and CD4+ cell counts in a sample of patients with CD4+ cell counts \<= 200/mm3 who are enrolled in protocol CPCRA 042.\] AR therapy is rapidly becoming the standard of care for the treatment of HIV infection. AR therapy provides the best opportunity for maximizing viral suppression, reducing toxicity and delaying the emergence of resistant strains. The newest class of AR agents, the HIV protease inhibitors, exhibits the most potent anti-HIV effects described to date. This study will compare 2 protease inhibitors, NFV and RTV for efficacy and safety in a population with advanced HIV disease, who are taking various background nucleoside therapies.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible patients will be randomized either to NFV plus background AR nucleoside therapy or to RTV plus background AR nucleoside therapy. Background AR therapy may also be no background therapy, although use of protease inhibitors as monotherapy is not recommended unless there is no alternative. Patients will be allowed to cross over to the alternate protease inhibitor if they reach a primary study endpoint. Data will be collected every 4 months.
\[AS PER AMENDMENT 10/2/97: Patients assigned to the NFV arm who develop a significant intolerance may switch to RTV or IDV; those assigned to the RTV arm who develop a significant intolerance are encouraged to switch to IDV (NFV allowed if IDV contraindicated). Switchover for intolerance is strongly discouraged during the first 4 weeks of follow-up. Patients initially assigned to NFV therapy who experience disease progression may switch to RTV; if RTV is not tolerated, patients may switch to IDV. Because of the cross-resistance between RTV and IDV, patients who progress on RTV should switch to NFV.\] \[AS PER AMENDMENT 12/15/98: Patients originally assigned to NFV who experience poor virologic control or disease progression should change to RTV or IDV or enroll in the PIP protocol (CPCRA 057). Conversely, patients originally assigned to RTV should change to NFV or enroll in the PIP protocol (such patients continue to be followed on this study). Because of cross-resistance between RTV and IDV, change from RTV to IDV is discouraged. Determination of poor virologic control or disease progression is at the discretion of the patient's clinician. Change in background antiretroviral therapy should occur at the same time that the protease inhibitor is changed for poor virologic control or progression; the choice of new background antiretroviral agents is at the discretion of the clinician.\] Randomization is stratified by clinical site.\] \[AS PER AMENDMENT 3/11/98: SUBSTUDY CPCRA 045: At least 600 patients (\>= 400 from CPCRA sites and \>= 200 from CTN sites) will be enrolled in the substudy. These patients will have a plasma sample collected for HIV RNA and genotypic resistance within 30 days prior to randomization, at the 1-month visit, and at the q-4-month study visits thereafter until the end of the study. CD4+ cell counts will be done at the 1-month visit and at the q-4-month study visits until the end of the study. A subset of patients will also have immunophenotyping of CD4+ and CD8+ cell TCR V-beta clones carried out before and during treatment. Another subset of patients at selected sites will have viral cultures performed for phenotypic drug sensitivity testing.
Initially, specimens for 50 randomly chosen patients in the group originally assigned RTV will be identified for resistance testing. Of this group, specimens for those who have received RTV/IDV for more than 1 month will be analyzed for genotypic resistance to obtain an estimate of the rate of resistance development and to estimate the risk of disease progression associated with resistance to RTV/ZDV. Based on these estimates, determination will be made of the total number of patients and specimens in both treatment groups in order to address the primary objective of comparing genotypic resistance in the two groups.\]
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Indinavir sulfate
Ritonavir
Nelfinavir mesylate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Background AR nucleoside therapy is required, although background AR therapy may also be no background therapy. However, the use of protease inhibitors is not recommended as monotherapy unless there is no other alternative. Therefore, patients who are not on AR treatment may be enrolled at the discretion of the clinician.
Allowed:
* Saquinavir.
Patients must have:
* Documented HIV infection.
* A CD4+ cell count \<= 100/mm3 within 3 months prior to the study. \[AS PER AMENDMENT 3/11/98: CD4+ cell count \<= 200/mm3 any time prior to entry\].
* Parental consent if patient is \< 18 years old.
Prior Medication:
Allowed:
* Saquinavir (SQV).
Exclusion Criteria
Patients with the following symptoms or conditions are excluded:
* Stage 2 or greater AIDS dementia complex.
* \[AS PER AMENDMENT 10/2/97: Any acute disease or condition that would, in the physician's judgement, contraindicate starting NFV or RTV.\]
* Known hypersensitivity to RTV or any of its ingredients (for patients assigned to RTV therapy).
Concurrent Medication:
Excluded:
* Concomitant use of protease inhibitors.
* Concomitant treatments that cannot be discontinued, and in the physician's judgement, should not be taken with NFV or RTV.
AS PER AMENDMENT 10/2/97:
* For patients randomized to NFV:
* Concomitant therapy with terfenadine, astemizole, cisapride, triazolam, midazolam, ergot derivatives, amiodarone, quinidine, or rifampin.
For patients randomized to IDV:
* Concomitant therapy with terfenadine, astemizole, cisapride, triazolam, midazolam, and rifampin.
Patients with any of the following prior symptoms are excluded:
AS PER AMENDMENT 10/2/97:
* History of clinically significant hypersensitivity reaction to any component of NFV tablets (for patients assigned to NFV therapy).
Prior Medication:
Excluded:
* Prior use of protease inhibitors except SQV.
\[AS PER AMENDMENT 10/2/97:
* Prior use of IDV for more than 4 weeks or other protease inhibitors (except SQV) for any prior duration.\]
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Perez G
Role: STUDY_CHAIR
MacArthur R
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Community Consortium / UCSF
San Francisco, California, United States
Community Consortium of San Francisco
San Francisco, California, United States
Denver Community Program for Clinical Research on AIDS
Denver, Colorado, United States
Denver CPCRA / Denver Pub Hlth / Rocky Mt Cancer Ctr Aurora
Denver, Colorado, United States
Denver CPCRA / Denver Public Hlth
Denver, Colorado, United States
Infectious Disease Physicians / Northern Virginia
Washington D.C., District of Columbia, United States
Timothy A Price
Washington D.C., District of Columbia, United States
Veterans Administration Med Ctr / Regional AIDS Program
Washington D.C., District of Columbia, United States
Washington Reg AIDS Prog / Dept of Infect Dis
Washington D.C., District of Columbia, United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
AIDS Research Alliance - Chicago
Chicago, Illinois, United States
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
New Orleans, Louisiana, United States
Louisiana Community AIDS Research Program
New Orleans, Louisiana, United States
Baltimore TRIALS
Baltimore, Maryland, United States
Westat / NICHD
Rockville, Maryland, United States
Comprehensive AIDS Alliance of Detroit
Detroit, Michigan, United States
Wayne State Univ / Univ Hlth Ctr
Detroit, Michigan, United States
Henry Ford Hosp
Detroit, Michigan, United States
Mercer Area Early Intervention Services
Camden, New Jersey, United States
Southern New Jersey AIDS Clinical Trials
Camden, New Jersey, United States
Southern New Jersey AIDS Cln Trials / Dept of Med
Camden, New Jersey, United States
New Jersey Community Research Initiative
Newark, New Jersey, United States
North Jersey Community Research Initiative
Newark, New Jersey, United States
Partners in Research - New Mexico
Albuquerque, New Mexico, United States
Partners Research
Albuquerque, New Mexico, United States
Harlem AIDS Treatment Group / Harlem Hosp Ctr
New York, New York, United States
Harlem AIDS Treatment Group
New York, New York, United States
Portland Veterans Adm Med Ctr / Rsch & Education Grp
Portland, Oregon, United States
The Research and Education Group
Portland, Oregon, United States
Philadelphia FIGHT
Philadelphia, Pennsylvania, United States
Saint Joseph's Hosp
Philadelphia, Pennsylvania, United States
Richmond AIDS Consortium
Richmond, Virginia, United States
Saint Paul's Hosp
Vancouver, British Columbia, Canada
QEII Health Science Centre
Halifax, Nova Scotia, Canada
Saint Joseph's Hosp
London, Ontario, Canada
Ottawa Gen Hosp
Ottawa, Ontario, Canada
Sunnybrook Health Science Centre
Toronto, Ontario, Canada
Toronto Gen Hosp
Toronto, Ontario, Canada
Wellesley Hosp
Toronto, Ontario, Canada
Hotel - Dieu de Montreal
Montreal, Quebec, Canada
Montreal Chest Institute
Montreal, Quebec, Canada
SMBD-Jewish Gen Hosp
Montreal, Quebec, Canada
Centre De Recherche En Infectiologie
Ste-Foy, Quebec, Canada
Royal Univ Hosp
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
MacArthur RD, Perez G, Walmsley S, Baxter J, Neaton J, Wentworth D. CD4 cell count is a better predictor of disease progression than HIV RNA level in persons with advanced HIV infection on highly active antiretroviral therapy. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 203)
Perez G, MacArthur RD, Walmsley S, Baxter JA, Mullin C, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS; Canadian Trials Network. A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clin Trials. 2004 Jan-Feb;5(1):7-18. doi: 10.1310/N11F-NK93-MUMR-A1VV.
MacArthur RD, Perez G, Walmsley S, Baxter JD, Mullin CM, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) 042/045; Canadian HIV Trials Network (CTN) 102 Protocol Teams. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials. 2005 May-Jun;6(3):127-35. doi: 10.1310/A9B9-RQD7-U8KA-503U.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11592
Identifier Type: REGISTRY
Identifier Source: secondary_id
CPCRA 042
Identifier Type: -
Identifier Source: org_study_id